Healthcare Industry News:  Bard 

Devices

 News Release - June 29, 2011

Bovine Carotid Artery (BCA) For Hemodialysis Access: 3-Year Prospective, Randomized Clinical Study at Massachusetts General Hospital Confirms Superiority of Artegraft to Cuffed ePTFE

North Brunswick, NJ-- The Journal of Vascular Surgery, in its June 2011 issue, has published the clinical results of a three-year prospective, randomized study comparing Artegraft(R) (Bovine Carotid Artery) to Bard Venaflo(R) for hemodialysis access. The study's conclusion: The BCA graft is an excellent option for patients on hemodialysis who are not eligible for native arteriovenous fistulas, as these grafts required fewer interventions than the ePTFE grafts to maintain patency.

Artegraft vs Venaflo

Overall Primary Patency Rate at 1 Year 60% vs 10%

Assisted Primary Patency Rate at 1 Year 60% vs 20%

Assisted Primary Patency Rate at 2 Years 40% vs 14%

Less Thrombosis and Fewer Interventions with BCA

No Pseudoaneurysms with BCA

Contact:
Rick Gibson
President & CEO
Artegraft, Inc.
732-422-8333
www.artegraft.com


Source: Artegraft

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.